IP
KRBP

Intellectus Partners’s Kiromic BioPharma, Inc. Common Stock KRBP Stock Holding History

Intellectus Partners’s Portfolio KRBP Stock Details KRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-3,295
Closed -$303K – 300
2021
Q3 		$303K Buy
3,295
+798
+32% +$82.6K 0.07% 224
2021
Q2 		$360K Buy
2,497
+1,225
+96% +$307K 0.08% 216
2021
Q1 		$359K Buy
1,272
+97
+8% +$28.4K 0.1% 203
2020
Q4 		$299K Buy
+1,175
New +$334K 0.09% 199

Other funds holding KRBP

KC
Kepos Capital New York $61.3M AUM 12.13% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
LCM
Lynwood Capital Management Toronto, Ontario, Canada $16.9M AUM 19.31% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
ZCA
Zeke Capital Advisors Berwyn, Pennsylvania $1.53B AUM 17.37% 1-Year Est. Return
RAM
Redmond Asset Management Henrico, Virginia $366M AUM 10.64% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Intellectus Partners's KRBP Position: Q4 2021 in Review

Intellectus Partners sold out of Kiromic BioPharma, Inc. Common Stock (KRBP) in Q4 2021, closing a stake of 3,295 shares — an estimated $303K sold.

Intellectus Partners first reported a position in KRBP in Q4 2020 and held it in 4 quarters. The position peaked at $360K in Q2 2021. 20 funds tracked by Wall St. Rank hold KRBP as of Q4 2021.

  • Intellectus Partners reported no remaining Kiromic BioPharma, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • Intellectus Partners sold 3,295 Kiromic BioPharma, Inc. Common Stock shares in Q4 2021, an estimated $303K.
  • Intellectus Partners first reported a position in Kiromic BioPharma, Inc. Common Stock in Q4 2020 and held it in 4 quarters.
  • Intellectus Partners's Kiromic BioPharma, Inc. Common Stock position peaked at $360K in Q2 2021.
  • 20 funds tracked by Wall St. Rank held Kiromic BioPharma, Inc. Common Stock as of Q4 2021.

Based on Intellectus Partners's 13F filing for Q4 2021, filed 14 Feb 2022.